[Commentary on] Should the FDA approval process for weight-loss drugs be modified?

November 2011
American Journal of Health-System Pharmacy;11/1/2011, Vol. 68 Issue 21, p2094
Academic Journal
The author highlights that lorcaserin, a weight loss drug, was not approved for marketing by the FDA, and mentions the weight loss combination of phentermine and fenfluramine (fen–phen). He comments on the lack of options for the medical treatment of obesity, and states that many obesity treatment specialists feel the FDA process for approval of new weight-loss drugs needs to be changed. The criteria should include not just weight loss, but also the success rates for weight-loss maintenance.


Related Articles

  • Weight loss category gains competitor in Qsymia. Weinstein, Deborah // Medical Marketing & Media;Aug2012, Vol. 47 Issue 8, p10 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) of two weight loss drugs, Belviq from Arena Pharmaceuticals Inc. and Qsymia from Vivus Inc.

  • FDA Approves First New Anti-Obesity Drug in Years. Elliott, William T. // Internal Medicine Alert;7/15/2012 Supplement, p1 

    The article informs that the U.S. Food and Drug Administration (FDA) has approved the anti-obesity drug Lorcaserin.

  • FDA denies approval of weight-loss drug.  // Endocrine Today;Feb2011, Vol. 9 Issue 2, p4 

    The article reports on a response letter sent by the U.S. Food and Drug Administration (FDA) in which they claimed that a new drug application for combination naltrexone plus bupropion extended-release tablets for obesity treatment was not approved.

  • Drugs in the News.  // Clarendon Enterprise (TX);7/11/2013, Vol. 24 Issue 28, p10 

    The article reports on the approval of the weight reducing drug Belviq (lorcaserin) by the Food and Drug Administration (FDA) in June 2012 as well as its release in the U.S. market.

  • Lorcaserin: A novel, selective 5-HT2C-receptor agonist for the treatment of obesity. Pauli, Maribeth // Formulary;Jun2010, Vol. 45 Issue 6, p180 

    The article discusses research into the use of the drug lorcaserin for the treatment of obesity. Pharmacologic treatments for obesity are meant to supplement other treatments including lifestyle modification and behavioral therapy. Lorcaserin is a selective 5-HT2C-receptor agonist which has been...

  • Weight loss without cardiac side effects. Elliott, William T. // Primary Care Reports;Sep2010 Pharmacology, p1 

    This article reports on the move made by Arena Pharmaceuticals to file a new drug application with the U.S. Food and Drug Administration (FDA) for lorcaserin, a selective serotonin 2C-receptor agonist used in weight-loss medication. It is noted that the drug will likely get a formal review in...

  • FDA Lorcaserin Panel Void of Carcinogenicity Experts. Young, Donna // BioWorld Today;9/20/2010, Vol. 21 Issue 181, p1 

    The article reports that the U.S. Food and Drug Administration's (FDA) lack of any carcinogenicity expertise appears to be the reason for its rejection of the weight loss drug Lorcaserin by Arena Pharmaceuticals Inc. The FDA panel that voted against the approval of lorcaserin, acknowledged that...

  • Arena Rises on Lorcaserin FDA Briefing Docs Ahead of EMDAC. Shaffer, Catherine // BioWorld Today;5/9/2012, Vol. 23 Issue 90, p1 

    The article focuses on the briefing documents released in advance of the May 10, 2010 meeting of the Endocronological and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drugs Administration (FDA) concerning weight loss drug Lorqess of Arena Pharmaceuticals. The documents...

  • Qnexa's Fate to Serve as a Guide for Other Obesity Drugs. Serebrov, Mari // BioWorld Today;7/12/2012, Vol. 23 Issue 134, p1 

    The article focuses on Vivus Inc.'s drug application with the U.S. Food and Drug Administration (FDA) for its weight-loss drug Qnexa. The drug combines phentermine, an appetite suppressant, with an anticonvulsant topiramate. If approved, it will open up a new lane for weight-loss drugs...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics